[HTML][HTML] Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy

Y Fan, Y Gao, L Nie, T Hou, W Dan, Z Wang, T Liu… - Molecular cell, 2023 - cell.com
Summary Cyclic GMP-AMP synthase (cGAS) binds pathogenic and other cytoplasmic
double-stranded DNA (dsDNA) to catalyze the synthesis of cyclic GMP-AMP (cGAMP), which …

[HTML][HTML] Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

RC Acúrcio, S Pozzi, B Carreira, M Pojo… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Background Inhibiting programmed cell death protein 1 (PD-1) or PD-ligand 1 (PD-L1) has
shown exciting clinical outcomes in diverse human cancers. So far, only monoclonal …

Designing peptide-based nanoinhibitors of programmed cell death ligand 1 (PD-L1) for enhanced chemo-immunotherapy

F Xie, S Tang, Y Zhang, Y Zhao, Y Lin, Y Yao… - ACS …, 2024 - ACS Publications
The combination of immune checkpoint blockade (ICB) and chemotherapy has shown
significant potential in the clinical treatment of various cancers. However, circulating …

[HTML][HTML] Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy

S Cai, Z Chen, Y Wang, M Wang, J Wu, Y Tong… - Theranostics, 2021 - ncbi.nlm.nih.gov
The binding between the immune checkpoints, programmed cell death ligand 1 (PD-L1) and
programmed cell death 1 (PD-1), compromises T-cell-mediated immune surveillance …

A Totipotent “All‐In‐One” Peptide Sequentially Blocks Immune Checkpoint and Reverses the Immunosuppressive Tumor Microenvironment

L Zhang, Z Jiang, X Yang, Y Qian, M Wang… - Advanced …, 2023 - Wiley Online Library
Immune checkpoint blockade combined with reversal of the immunosuppressive tumor
microenvironment (TME) can dramatically enhance anti‐tumor immunity, which can be …

[HTML][HTML] FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer

J Liu, L Wei, N Hu, D Wang, J Ni, S Zhang… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Activation of the programmed cell death protein 1/programmed death-ligand 1
(PD-1/PD-L1) pathway has been extensively described as a pivotal mechanism to escape …

[HTML][HTML] Quantifying PD-L1 expression to monitor immune checkpoint therapy: opportunities and challenges

S Nimmagadda - Cancers, 2020 - mdpi.com
Simple Summary Malignant cells hijack the regulatory roles of immune checkpoint proteins
for immune evasion and survival. Therapeutics blocking those proteins can restore the …

[HTML][HTML] Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy

Z Liu, M Xiao, Y Mo, H Wang, Y Han… - … journal of biological …, 2022 - ncbi.nlm.nih.gov
Protein palmitoylation is an increasingly investigated form of post-translational lipid
modification that affects protein localization, accumulation, secretion and function. Recently …

Inhibition of gasdermin D palmitoylation by disulfiram is crucial for the treatment of myocardial infarction

Z Zhuang, J Gu, BO Li, L Yang - Translational Research, 2024 - Elsevier
To investigate the role of S-palmitoylation in pyroptosis following acute myocardial infarction
(AMI). Myocardial ischemic injury is mainly related to the death of terminally differentiated …

[HTML][HTML] Protein palmitoylation-mediated palmitic acid sensing causes blood-testis barrier damage via inducing ER stress

X Ge, Z He, C Cao, T Xue, J Jing, R Ma, W Zhao, L Liu… - Redox Biology, 2022 - Elsevier
Blood-testis barrier (BTB) damage promotes spermatogenesis dysfunction, which is a critical
cause of male infertility. Dyslipidemia has been correlated with male infertility, but the major …